Share Price and Basic Stock Data
Last Updated: November 22, 2025, 9:55 am
| PEG Ratio | 16.35 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Syngene International Ltd operates in the Miscellaneous industry and has showcased robust revenue growth, with sales reported at ₹3,193 Cr for the financial year ending March 2023, up from ₹2,604 Cr in March 2022. The company recorded a steady increase in quarterly sales, peaking at ₹994 Cr in March 2023, before slightly declining to ₹808 Cr in June 2023, and rebounding to ₹910 Cr in September 2023. The trailing twelve months (TTM) sales stood at ₹3,747 Cr, indicating a strong demand for its services. The firm has successfully expanded its operational capabilities, as reflected in its operating profit margin (OPM), which hovered around 30% for the fiscal year 2023, suggesting that it has maintained efficient cost management alongside revenue growth.
Profitability and Efficiency Metrics
Profitability metrics for Syngene reveal a net profit of ₹464 Cr for the financial year ending March 2023, translating to an earnings per share (EPS) of ₹11.57. The company’s return on equity (ROE) stood at 10.5%, while its return on capital employed (ROCE) was reported at 13.5%, indicative of effective capital utilization. The interest coverage ratio (ICR) of 20.97x underscores the firm’s ability to meet its interest obligations comfortably. However, the OPM has shown fluctuations, declining to 24% in the latest quarter, which could raise concerns regarding cost management moving forward. The cash conversion cycle (CCC) at -23 days reflects efficient working capital management, enabling Syngene to convert investments into cash quickly.
Balance Sheet Strength and Financial Ratios
Syngene International’s balance sheet reveals a conservative financial structure, with total borrowings reported at ₹582 Cr against reserves of ₹4,332 Cr. The debt-to-equity ratio stands at 0.02, indicating minimal leverage and a strong equity base. The company’s current ratio of 1.64 and quick ratio of 1.53 suggest a healthy liquidity position, enabling it to cover short-term obligations effectively. Financial ratios such as the price-to-book value (P/BV) at 6.18x position Syngene as a premium investment, albeit with a high valuation compared to sector norms. This high valuation could be a double-edged sword, as it may limit upside potential in a market correction but also signifies strong investor confidence in the company’s future prospects.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Syngene International indicates a significant share of institutional ownership, with Foreign Institutional Investors (FIIs) holding 16.31% and Domestic Institutional Investors (DIIs) at 24.62%. Promoters hold a majority stake of 52.68%, reflecting a solid commitment to the company’s growth. The gradual decline in promoter shareholding from 64.86% in December 2022 to the current level could raise questions about insider confidence. However, the increase in DII ownership from 7.03% in December 2022 to 24.62% indicates growing institutional interest and confidence in Syngene’s long-term growth trajectory. The overall number of shareholders stood at 1,36,061, which adds to the company’s stability and suggests a diverse investor base.
Outlook, Risks, and Final Insight
Looking forward, Syngene International faces both opportunities and risks. The company could benefit from increasing global demand for biopharmaceutical services, particularly in contract research and manufacturing, positioning it for potential revenue growth. However, risks include rising operational costs and potential regulatory challenges in the biopharmaceutical industry. The company’s ability to maintain its profitability amid these challenges will be crucial. Additionally, fluctuations in market sentiment could impact its high valuation. Should operational efficiencies improve and revenue growth continue, Syngene might enhance its competitive edge. Conversely, any downturn in demand or significant cost overruns could adversely affect its financial performance. Investors should remain vigilant about these dynamics as they assess the company’s future prospects.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Syngene International Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mipco Seamless Rings (Gujarat) Ltd | 9.35 Cr. | 26.1 | 37.4/22.0 | 3.71 | 0.00 % | % | % | 10.0 | |
| MPIL Corporation Ltd | 25.2 Cr. | 443 | 787/443 | 242 | 0.10 % | 12.8 % | 15.5 % | 10.0 | |
| FGP Ltd | 11.9 Cr. | 10.0 | 13.7/7.32 | 3.09 | 0.00 % | 0.00 % | 0.89 % | 10.0 | |
| Logica Infoway Ltd | 394 Cr. | 222 | 272/173 | 28.8 | 53.0 | 0.00 % | 14.3 % | 14.1 % | 10.0 |
| CRP Risk Management Ltd | 10.8 Cr. | 6.18 | 10.6/5.61 | 34.6 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| Industry Average | 8,143.50 Cr | 260.55 | 41.50 | 104.34 | 0.03% | 48.42% | 7.44% | 9.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 644 | 768 | 786 | 994 | 808 | 910 | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 |
| Expenses | 472 | 552 | 555 | 680 | 596 | 656 | 622 | 600 | 620 | 646 | 660 | 674 | 668 |
| Operating Profit | 173 | 216 | 231 | 314 | 212 | 254 | 232 | 317 | 170 | 245 | 284 | 344 | 206 |
| OPM % | 27% | 28% | 29% | 32% | 26% | 28% | 27% | 35% | 22% | 27% | 30% | 34% | 24% |
| Other Income | 16 | 15 | 17 | 23 | 24 | 14 | 26 | 16 | 50 | 16 | 18 | 19 | 18 |
| Interest | 9 | 12 | 14 | 10 | 10 | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 |
| Depreciation | 86 | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 |
| Profit before tax | 93 | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 240 | 101 |
| Tax % | 20% | 22% | 22% | 23% | 24% | 23% | 19% | 10% | 25% | 23% | 27% | 24% | 14% |
| Net Profit | 74 | 102 | 110 | 179 | 93 | 116 | 112 | 189 | 76 | 106 | 131 | 183 | 87 |
| EPS in Rs | 1.84 | 2.54 | 2.73 | 4.45 | 2.32 | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.55 | 2.15 |
Last Updated: August 1, 2025, 10:45 am
Below is a detailed analysis of the quarterly data for Syngene International Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 874.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,018.00 Cr. (Mar 2025) to 874.00 Cr., marking a decrease of 144.00 Cr..
- For Expenses, as of Jun 2025, the value is 668.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 674.00 Cr. (Mar 2025) to 668.00 Cr., marking a decrease of 6.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 206.00 Cr.. The value appears to be declining and may need further review. It has decreased from 344.00 Cr. (Mar 2025) to 206.00 Cr., marking a decrease of 138.00 Cr..
- For OPM %, as of Jun 2025, the value is 24.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Mar 2025) to 24.00%, marking a decrease of 10.00%.
- For Other Income, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 12.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 12.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 111.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 106.00 Cr. (Mar 2025) to 111.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 101.00 Cr.. The value appears to be declining and may need further review. It has decreased from 240.00 Cr. (Mar 2025) to 101.00 Cr., marking a decrease of 139.00 Cr..
- For Tax %, as of Jun 2025, the value is 14.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Mar 2025) to 14.00%, marking a decrease of 10.00%.
- For Net Profit, as of Jun 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 183.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 96.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.15. The value appears to be declining and may need further review. It has decreased from 4.55 (Mar 2025) to 2.15, marking a decrease of 2.40.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:20 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 | 3,747 |
| Expenses | 949 | 1,289 | 1,394 | 1,507 | 1,806 | 2,251 | 2,472 | 2,598 | 2,714 |
| Operating Profit | 474 | 537 | 618 | 678 | 798 | 942 | 1,017 | 1,045 | 1,033 |
| OPM % | 33% | 29% | 31% | 31% | 31% | 30% | 29% | 29% | 28% |
| Other Income | 53 | 75 | 153 | 94 | 20 | 63 | 77 | 101 | 70 |
| Interest | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 53 | 53 |
| Depreciation | 131 | 164 | 219 | 274 | 310 | 366 | 426 | 433 | 442 |
| Profit before tax | 372 | 415 | 517 | 469 | 484 | 594 | 621 | 660 | 608 |
| Tax % | 18% | 20% | 20% | 14% | 18% | 22% | 18% | 25% | |
| Net Profit | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 496 | 468 |
| EPS in Rs | 7.64 | 8.29 | 10.30 | 10.12 | 9.88 | 11.57 | 12.69 | 12.33 | 11.63 |
| Dividend Payout % | 7% | 3% | 0% | 0% | 10% | 11% | 10% | 10% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 8.85% | 24.10% | -1.70% | -2.22% | 17.17% | 9.91% | -2.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 15.24% | -25.80% | -0.52% | 19.39% | -7.26% | -12.66% |
Syngene International Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 4% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 7% |
| 3 Years: | 5% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 12% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: November 9, 2025, 3:03 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 | 403 |
| Reserves | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 | 4,324 | 4,332 |
| Borrowings | 787 | 813 | 773 | 893 | 1,022 | 815 | 555 | 578 | 582 |
| Other Liabilities | 681 | 922 | 1,214 | 1,169 | 1,245 | 1,398 | 1,339 | 1,491 | 1,226 |
| Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 6,542 |
| Fixed Assets | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 | 2,802 | 3,049 |
| CWIP | 155 | 274 | 234 | 237 | 346 | 177 | 838 | 1,266 | 989 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 918 | 548 | 647 | 547 |
| Other Assets | 1,846 | 1,337 | 1,133 | 1,743 | 1,790 | 2,069 | 1,916 | 2,081 | 1,957 |
| Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 6,542 |
Below is a detailed analysis of the balance sheet data for Syngene International Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 403.00 Cr.. The value appears strong and on an upward trend. It has increased from 402.00 Cr. (Mar 2025) to 403.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,332.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,324.00 Cr. (Mar 2025) to 4,332.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Sep 2025, the value is 582.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 578.00 Cr. (Mar 2025) to 582.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,226.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,491.00 Cr. (Mar 2025) to 1,226.00 Cr., marking a decrease of 265.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be improving (decreasing). It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,049.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,802.00 Cr. (Mar 2025) to 3,049.00 Cr., marking an increase of 247.00 Cr..
- For CWIP, as of Sep 2025, the value is 989.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,266.00 Cr. (Mar 2025) to 989.00 Cr., marking a decrease of 277.00 Cr..
- For Investments, as of Sep 2025, the value is 547.00 Cr.. The value appears to be declining and may need further review. It has decreased from 647.00 Cr. (Mar 2025) to 547.00 Cr., marking a decrease of 100.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,957.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,081.00 Cr. (Mar 2025) to 1,957.00 Cr., marking a decrease of 124.00 Cr..
- For Total Assets, as of Sep 2025, the value is 6,542.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6,796.00 Cr. (Mar 2025) to 6,542.00 Cr., marking a decrease of 254.00 Cr..
Notably, the Reserves (4,332.00 Cr.) exceed the Borrowings (582.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -313.00 | -276.00 | -155.00 | -215.00 | 797.00 | 127.00 | -554.00 | -577.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 68 | 72 | 79 | 71 | 61 | 46 | 53 |
| Inventory Days | 82 | 30 | 18 | 41 | 87 | 141 | 94 | 60 |
| Days Payable | 195 | 154 | 156 | 167 | 113 | 109 | 100 | 136 |
| Cash Conversion Cycle | -44 | -56 | -66 | -47 | 45 | 92 | 40 | -23 |
| Working Capital Days | -48 | -103 | -172 | -66 | -43 | -14 | -27 | -51 |
| ROCE % | 17% | 17% | 14% | 13% | 15% | 15% | 14% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Focused Fund | 3,831,558 | 2.9 | 268.76 | 3,831,558 | 2025-04-22 17:25:19 | 0% |
| ICICI Prudential ELSS Tax Saver Fund | 3,400,267 | 1.92 | 238.51 | 3,400,267 | 2025-04-22 17:25:19 | 0% |
| UTI Flexi Cap Fund | 2,930,375 | 0.78 | 205.55 | 2,930,375 | 2025-04-22 17:25:19 | 0% |
| ICICI Prudential Focused Equity Fund | 2,288,353 | 2.46 | 160.52 | 2,288,353 | 2025-04-22 17:25:19 | 0% |
| PGIM India Midcap Opportunities Fund | 2,231,770 | 1.56 | 156.55 | 2,231,770 | 2025-04-22 17:25:19 | 0% |
| UTI Mid Cap Fund | 1,933,955 | 1.39 | 135.66 | 1,933,955 | 2025-04-22 17:25:19 | 0% |
| ICICI Prudential Multicap Fund | 1,811,685 | 1.23 | 127.08 | 1,811,685 | 2025-04-22 17:25:19 | 0% |
| ICICI Prudential Large & Mid Cap Fund | 1,780,039 | 1.22 | 124.86 | 1,780,039 | 2025-04-22 17:25:19 | 0% |
| ICICI Prudential Flexicap Fund | 1,671,586 | 0.87 | 117.25 | 1,671,586 | 2025-04-22 17:25:19 | 0% |
| Kotak Equity Arbitrage Fund - Regular Plan | 1,608,000 | 0.33 | 112.79 | 1,608,000 | 2025-04-22 17:25:19 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 12.35 | 12.71 | 11.59 | 9.94 | 10.18 |
| Diluted EPS (Rs.) | 12.34 | 12.69 | 11.51 | 9.82 | 10.11 |
| Cash EPS (Rs.) | 23.07 | 23.28 | 20.70 | 17.60 | 16.98 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 117.44 | 105.92 | 90.13 | 82.28 | 70.53 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 117.44 | 105.92 | 90.13 | 82.28 | 70.53 |
| Revenue From Operations / Share (Rs.) | 90.49 | 86.78 | 79.54 | 64.97 | 54.61 |
| PBDIT / Share (Rs.) | 27.67 | 27.49 | 25.04 | 21.18 | 18.41 |
| PBIT / Share (Rs.) | 16.92 | 16.89 | 15.91 | 13.45 | 11.55 |
| PBT / Share (Rs.) | 16.40 | 15.44 | 14.79 | 12.09 | 11.73 |
| Net Profit / Share (Rs.) | 12.33 | 12.69 | 11.57 | 9.88 | 10.12 |
| NP After MI And SOA / Share (Rs.) | 12.33 | 12.69 | 11.57 | 9.88 | 10.12 |
| PBDIT Margin (%) | 30.57 | 31.67 | 31.48 | 32.59 | 33.71 |
| PBIT Margin (%) | 18.69 | 19.46 | 20.00 | 20.70 | 21.14 |
| PBT Margin (%) | 18.11 | 17.79 | 18.59 | 18.60 | 21.48 |
| Net Profit Margin (%) | 13.62 | 14.61 | 14.54 | 15.19 | 18.53 |
| NP After MI And SOA Margin (%) | 13.62 | 14.61 | 14.54 | 15.19 | 18.53 |
| Return on Networth / Equity (%) | 10.49 | 11.97 | 12.83 | 12.00 | 14.35 |
| Return on Capital Employeed (%) | 12.61 | 13.56 | 13.75 | 12.43 | 12.31 |
| Return On Assets (%) | 7.30 | 8.29 | 7.96 | 7.11 | 8.29 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | 0.13 | 0.16 | 0.18 |
| Total Debt / Equity (X) | 0.02 | 0.03 | 0.15 | 0.23 | 0.27 |
| Asset Turnover Ratio (%) | 0.56 | 0.58 | 0.55 | 0.49 | 0.48 |
| Current Ratio (X) | 1.64 | 1.71 | 2.04 | 1.79 | 1.59 |
| Quick Ratio (X) | 1.53 | 1.50 | 1.76 | 1.65 | 1.54 |
| Inventory Turnover Ratio (X) | 4.70 | 3.06 | 3.52 | 6.45 | 13.01 |
| Dividend Payout Ratio (NP) (%) | 10.13 | 9.86 | 8.63 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 5.41 | 5.37 | 4.82 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 89.87 | 90.14 | 91.37 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 94.59 | 94.63 | 95.18 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 20.97 | 23.41 | 22.24 | 35.22 | 26.58 |
| Interest Coverage Ratio (Post Tax) (X) | 9.74 | 12.04 | 11.27 | 18.70 | 14.35 |
| Enterprise Value (Cr.) | 28558.13 | 27786.54 | 23908.84 | 24195.45 | 21863.70 |
| EV / Net Operating Revenue (X) | 7.84 | 7.96 | 7.49 | 9.29 | 10.01 |
| EV / EBITDA (X) | 25.64 | 25.15 | 23.78 | 28.50 | 29.69 |
| MarketCap / Net Operating Revenue (X) | 8.02 | 8.09 | 7.47 | 9.19 | 9.95 |
| Retention Ratios (%) | 89.86 | 90.13 | 91.36 | 0.00 | 0.00 |
| Price / BV (X) | 6.18 | 6.63 | 6.60 | 7.25 | 7.70 |
| Price / Net Operating Revenue (X) | 8.02 | 8.09 | 7.47 | 9.19 | 9.95 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Syngene International Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 12.35. This value is within the healthy range. It has decreased from 12.71 (Mar 24) to 12.35, marking a decrease of 0.36.
- For Diluted EPS (Rs.), as of Mar 25, the value is 12.34. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.34, marking a decrease of 0.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 23.07. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 23.07, marking a decrease of 0.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 117.44. It has increased from 105.92 (Mar 24) to 117.44, marking an increase of 11.52.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 90.49. It has increased from 86.78 (Mar 24) to 90.49, marking an increase of 3.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 27.67. This value is within the healthy range. It has increased from 27.49 (Mar 24) to 27.67, marking an increase of 0.18.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.92. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 16.92, marking an increase of 0.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 16.40. This value is within the healthy range. It has increased from 15.44 (Mar 24) to 16.40, marking an increase of 0.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 12.33. This value is within the healthy range. It has decreased from 12.69 (Mar 24) to 12.33, marking a decrease of 0.36.
- For PBDIT Margin (%), as of Mar 25, the value is 30.57. This value is within the healthy range. It has decreased from 31.67 (Mar 24) to 30.57, marking a decrease of 1.10.
- For PBIT Margin (%), as of Mar 25, the value is 18.69. This value is within the healthy range. It has decreased from 19.46 (Mar 24) to 18.69, marking a decrease of 0.77.
- For PBT Margin (%), as of Mar 25, the value is 18.11. This value is within the healthy range. It has increased from 17.79 (Mar 24) to 18.11, marking an increase of 0.32.
- For Net Profit Margin (%), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 10. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.62. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 13.62, marking a decrease of 0.99.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.49. This value is below the healthy minimum of 15. It has decreased from 11.97 (Mar 24) to 10.49, marking a decrease of 1.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.61. This value is within the healthy range. It has decreased from 13.56 (Mar 24) to 12.61, marking a decrease of 0.95.
- For Return On Assets (%), as of Mar 25, the value is 7.30. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 7.30, marking a decrease of 0.99.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.64. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.64, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.53. This value is within the healthy range. It has increased from 1.50 (Mar 24) to 1.53, marking an increase of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.70. This value is within the healthy range. It has increased from 3.06 (Mar 24) to 4.70, marking an increase of 1.64.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.13. This value is below the healthy minimum of 20. It has increased from 9.86 (Mar 24) to 10.13, marking an increase of 0.27.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.41. This value is below the healthy minimum of 20. It has increased from 5.37 (Mar 24) to 5.41, marking an increase of 0.04.
- For Earning Retention Ratio (%), as of Mar 25, the value is 89.87. This value exceeds the healthy maximum of 70. It has decreased from 90.14 (Mar 24) to 89.87, marking a decrease of 0.27.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.59. This value exceeds the healthy maximum of 70. It has decreased from 94.63 (Mar 24) to 94.59, marking a decrease of 0.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.97. This value is within the healthy range. It has decreased from 23.41 (Mar 24) to 20.97, marking a decrease of 2.44.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 9.74. This value is within the healthy range. It has decreased from 12.04 (Mar 24) to 9.74, marking a decrease of 2.30.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28,558.13. It has increased from 27,786.54 (Mar 24) to 28,558.13, marking an increase of 771.59.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.84. This value exceeds the healthy maximum of 3. It has decreased from 7.96 (Mar 24) to 7.84, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 25.64. This value exceeds the healthy maximum of 15. It has increased from 25.15 (Mar 24) to 25.64, marking an increase of 0.49.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
- For Retention Ratios (%), as of Mar 25, the value is 89.86. This value exceeds the healthy maximum of 70. It has decreased from 90.13 (Mar 24) to 89.86, marking a decrease of 0.27.
- For Price / BV (X), as of Mar 25, the value is 6.18. This value exceeds the healthy maximum of 3. It has decreased from 6.63 (Mar 24) to 6.18, marking a decrease of 0.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 3. It has decreased from 8.09 (Mar 24) to 8.02, marking a decrease of 0.07.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Syngene International Ltd:
- Net Profit Margin: 13.62%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.61% (Industry Average ROCE: 48.42%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.49% (Industry Average ROE: 7.44%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 9.74
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.53
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 54.2 (Industry average Stock P/E: 41.5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.62%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Biocon SEZ, Biocon Park, Bengaluru Karnataka 560099 | investor@syngeneintl.com http://www.syngeneintl.com |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Kiran Mazumdar Shaw | Non Executive Chairman |
| Mr. Peter Bains | Managing Director & CEO |
| Prof. Catherine Rosenberg | Non Executive Director |
| Ms. Vinita Bali | Lead Independent Director |
| Mr. Nilanjan Roy | Independent Director |
| Dr. Kush Parmar | Independent Director |
| Ms. Sharmila Abhay Karve | Independent Director |
| Dr. Vijay Kuchroo | Independent Director |
| Mr. Manja Boerman | Independent Director |
FAQ
What is the intrinsic value of Syngene International Ltd?
Syngene International Ltd's intrinsic value (as of 22 November 2025) is 538.30 which is 14.42% lower the current market price of 629.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 25,359 Cr. market cap, FY2025-2026 high/low of 961/599, reserves of ₹4,332 Cr, and liabilities of 6,542 Cr.
What is the Market Cap of Syngene International Ltd?
The Market Cap of Syngene International Ltd is 25,359 Cr..
What is the current Stock Price of Syngene International Ltd as on 22 November 2025?
The current stock price of Syngene International Ltd as on 22 November 2025 is 629.
What is the High / Low of Syngene International Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Syngene International Ltd stocks is 961/599.
What is the Stock P/E of Syngene International Ltd?
The Stock P/E of Syngene International Ltd is 54.2.
What is the Book Value of Syngene International Ltd?
The Book Value of Syngene International Ltd is 118.
What is the Dividend Yield of Syngene International Ltd?
The Dividend Yield of Syngene International Ltd is 0.20 %.
What is the ROCE of Syngene International Ltd?
The ROCE of Syngene International Ltd is 13.5 %.
What is the ROE of Syngene International Ltd?
The ROE of Syngene International Ltd is 10.5 %.
What is the Face Value of Syngene International Ltd?
The Face Value of Syngene International Ltd is 10.0.